Elan, Biogen Idec get priority review for Tysabri application

Elan and Biogen Idec got a major boost Thursday evening when the FDA said it would provide a priority review for their request to bring Tysabri back onto the market for multiple sclerosis. The notification also confirmed the FDA's opinion that the biotech companies' application was complete. The accelerated review process cuts the FDA's response time from 10 months to six months. Tysabri was pulled from the market last February after it was linked to a lethal brain disease. It had been approved for marketing only months before and was expected to quickly emerge as a blockbuster drug.

- read this AP report for more